RECEIVED.

OCT 1 0 2002

TECH CENTER 1600/2900 PATENT ATTORNEY DOCKET NO.50125/051401

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jens Schletter

Art Unit:

Serial No.:

10/088,248

Examiner:

Filed:

March 15, 2002

Customer No.:

21559

Title:

PHARMACEUTICAL COMPOSITION IN THE FORM OF A

NUCLEIC ACID/LIPID COMPLEX, ITS PRODUCTION AND USE IN

GENE THERAPY

Assistant Commissioner For Patents Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

RECEIVED
NOV 2 0 2002
TECH CENTER 1600/2900

If there are any other charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 8 October 2002

Karen L. Elbing, Ph.D

Reg. No. 35,238

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

 $\label{localize} $$\Clark-w2k1\documents\\50125\50125.051001---IDS.wpd$$

SUBSTITUTE FORM PTO-1449 (MODIFIED)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Attorney Docket No. Serial No.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant Filing Date

(Use several sheets if necessary)

Group

Not Assigned Yet

(37 C.F.R. §1.98(b))

IDS Filed

October 9, 2002

U.S	S. P	'ΑΤ	EN'	TS
-----	------	-----	-----	----

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	6,200,304	Mar. 13, 2001	Schrader	604	509	1
	6,156,338	Dec. 5, 2000	Vacus et al.	424	450	~
	6,149,936	Nov. 21, 2000	Schrader et al.	424	450	
	6,146,887	Nov. 14, 2000	Schrader et al.	435	320.1	
	5,888,982	Mar. 30, 1999	Perrella et al.	514	44	
	5,888,821	Mar. 30, 1999	Reszka	435	458	
	5,827,703	Oct. 27, 1998	Debs et al.	435	172.3	
	5,811,406	Sep. 22, 1998	Szoka, Jr. et al.	514	44	
	5,753,262	May 19, 1998	Wyse et al.	424	450	
	5,756,353	May 26, 1998	Debs	435	375	
	5,676,954	Oct. 14, 1997	Brigham	424	450	
	5,658,565	Aug. 19, 1997	Billiar et al.	424	93.21	
	5,635,182	Jun. 3, 1997	McCoy et al.	424	192.1	
	5,614,503	Mar. 25, 1997	Chaudhary et al.	514	44	
	5,283,185	Feb. 1, 1994	Epand et al.	435	172.3	
	5,278,287	Jan. 11, 1994	Rollins et al.	530	351	
	5,212,073	May 18, 1993	Rollins et al.	435	69.5	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	. Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 99/17798	Apr. 15, 1999	WIPO			Yes
·····	WO 99/15206	Apr. 1, 1999	WIPO			Yes
	WO 99/05303	Feb. 4, 1999	WIPO			Yes
	WO 98/44953	Oct. 15, 1998	WIPO			Yes

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

			NT OF COMMERCE ADEMARK OFFICE	Attorney Docket No. Serial No.		50125/051001 10/088,248 Jens Schletter	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant Filing Date Group		March 15, 2002 Not Assigned Yet	
(37 C.F.R. §1.	98(b))			IDS Filed		October 9	3
	····	GN PATENT OR P	UBLISHED FOREIGN	I PATENT AF	PLICATIO	N	2
Examiner's Initials	Document Number	. Publication Date	Country o		Class	Subclass	Translatio (Yes/No)
	WO 98/44934	Oct. 15, 1998	WIPO				Yes
	WO 98/41192	Sep. 24, 1998	WIPO				Yes
	WO 98/22144	May 28, 1998	WIPO				Yes
	WO 98/17814	Apr. 30, 1998	WIPO				Yes
	WO 98/13026	Apr. 2, 1998	WIPO				Yes
	WO 98/12324	Mar. 26, 1998	WIPO				Yes
	WO 98/10748	Mar. 19, 1998	WIPO				Yes
	WO 98/08489	Mar. 5, 1998	WIPO				Yes
	WO 97/35982	Oct. 2, 1997	WIPO				Yes
	WO 96/41873	Dec. 27, 1996	WIPO				Yes
	WO 96/40964	Dec. 19, 1996	WIPO				Yes
	WO 96/40265	Dec. 19, 1996	WIPO				Yes
	WO 96/40067	Dec. 19, 1996	WIPO				Yes
	W0 96/34109	Oct. 31, 1996	WIPO				Yes
	WO 96/27393	Sep. 12, 1996	WIPO				Yes
	WO 96/26745	Sep. 6, 1996	WIPO				Yes
	WO 96/24333	Aug. 15, 1996	WIPO	-			Yes
	WO 96/20208	Jul. 4, 1996	WIPO				No
	WO 96/18372	Jun 20, 1996	WIPO				Yes
	EP 0891780A2	Jan. 20, 1999	EPO				No
	FR 2 754 272	Apr. 10, 1998	FRANCE				No
	DE 19729769A1	Jul. 11, 1997	GERMANY				No
	DE 19623916A1	Jun. 10, 1996	GERMANY				No
	DE 4411402A1	Mar. 31, 1994	GERMANY				No
EXAMINER	itial citation conside		DATE CO	NSIDERED			

			Sheet 3 of	 		
SUBSTITUTE	FORM PTO-1449 U.S. DEPARTMENT OF COMME	RCE Attorney Docket No.	50125/051001			
(MODIFIED)	PATENT AND TRADEMARK OF	FICE Serial No.	50125/051001 10/088,248 Jens Schletter March 15, 2002 Not Assigned Yet	NOV 2 n 2002		
		Applicant	Jens Schletter			
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	March 15, 2002	200;		
	(Use several sheets if necessary)	Group	Not Assigned Yet			
(37 C.F.R. §1.	98(b))	IDS Filed	October 9, 2002	5		
	OTHER DOCUMENTS (INCLUDING AUTHOR, TI	ITLE, DATE, PLACE OF PUBL	ICATION)			
	Anchordoquy et al., "Maintenance of Transfection Ra after Freeze-Drying and Rehydration", Arch. Biochem			es		
	Arras, et al., "Monocyte Activation in Angiogenesis ar 101(1): 40-50, 1998	nd Collateral Growth in the Rab	bit Hindlimb", J. Clin. Inve	est,		
	Behr et al., "Efficient gene transfer into mammalian p Proc. Natl. Acad. Sci. USA, 86: 6982-6986, 1989	rimary endocrine cells with lipo	polyamine-coated DNA",			
	Branden et al., "A peptide nucleic acid-nuclear localiz Nature Biotech., 17: 784-787, 1999	ration signal fusion that mediate	es nuclear transport of DN	NA",		
	Felgner et al., "Lipofection: A highly efficient, lipid-me USA, 84: 7413-7417, 1987	diated DNA-transfection proced	dure", <i>Proc. Natl. Acad.</i> S	ici.		
	Gao et al., "A Novel Cationic Liposome Reagent for E Biophys. Res. Commun., 179(1): 280-285, 1991	Efficient Transfecton of Mamma	lian Cells", <i>Biochem,</i>			
	Hancock et al., "Antibody-induced transplant arteriosc anti-apoptotic genes", <i>Nature Medicine</i> , 4(12): 1392-1		rpression of anti-oxidant a	and		
	Hicke et al., "DNA Aptamers Block L-Selection Functi	ion In Vivo", <i>J. Clin. Invest</i> , 98(12): 2688-2692, 1996			
	Hosang et al., "Porcine luteal cells express monocyte polymerase chain reaction and cDNA cloning", Biochem					
	Ito et al., "Monocyte Chemotactic Protein-1 Increases Artery Occlusion", <i>Circulation Res.</i> , 80: 829-837, 199		ductance After Femoral			
	Jia et al., "Distinct Expression and Function of the No Lung Allergic Inflammation", J. Exp. Med., 184: 1939-		te Chemotactic Protein-5	in		
	Karas et al. "Coronary Intimal Proliferation After Ballo Restenosis", <i>J. Am. Coll. Cardiol</i> , 20: 467-474, 1992	on Injury and Stenting in Swine	e: An Animal Model of			
	Kichler et al., "Influence of Membrane-Active Peptides Transfer", <i>Bioconjugate Chem.</i> , 8:213-221, 1997	s on Lipospermine/DNA Compl	ex Mediated Gene			
	Lechardeur et al., "Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer", Gene Therapy 6:482-497, 1999					
	Lu et al., "Expression of Thioredoxin Random Peptide Functional Fusions to Flagellin: A System Designed for 13: 366-372, 1995			γ,		
	Koivunen et al., "Identification of Receptor Ligands wi 40(5): 883-888, 1999	ith Phage Display Peptide Libra	ries", Journal of Nucl. Me	ed.,		
	McCoubrey Jr. et al., "Human Heme Oxygenase-2: C Evidence Suggesting That the Two HO-2 Transcripts Biochem, Biophys., 295(1): 13-20, 1992					
EXAMINER	DA	TE CONSIDERED		-		

		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFI		Attorney Docket No.	50125/051001	•
(MODIFIED)	(MODIFIED) PATENT AND TRADEMARK		KOFFICE	Serial No.	10/088,248	
	INFORMATION PLOCE COURT			Applicant	Jens Schletter.	ž.
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	March 15, 2002	<i>S</i> 1
	(Use several)	sheets if necessary)		Group	Not Assigned Yet	-511 VEINTER 1600/290
(37 C.F.R. §1.98(b))			IDS Filed	October 9, 2002	290	
	OTHER DOCU	IMENTS (INCLUDING AUTHO	R, TITLE, C	OATE, PLACE OF PUBL	CATION)	0
		al., "Isolation and Characteriza -3", Eur. J. Biochem., 247:725		NA from the rat brain th	at encodes hemoprotei	n
	Nabel et al., "Metl 1997	hods for Liposome-Mediated G	Sene Transf	er to the Arterial Wall", G	ene Ther. Protoc., 127	-133,
		Influence of Endosome-disrup,", Journal of Biol. Chem., 269(ng Synthetic Virus-like (Gene
	Sarafi et al., "Murine Monocyte Chemoattractant Protein (MCP)-5: A Novel CC Chemokine that is a Structural and Functional Homologue of Human MCP-1", <i>J. Exp. Med.</i> , 185(1): 99-109, 1997					
	Schwartz et al., "Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo", <i>Gene Therapy</i> , 6: 282-292, 1999					
	Schwartz et al., "Restenosis After Balloon Angioplasty: A Practical Proliferative Model in Porcine Coronary Arteries", Circulation, 82(6): 2190-2200, 1990					
	Soares et al., "Expression of heme oxygenase-1 can determine cardiac xenograft survival", <i>Nature Medicine</i> 4(9): 1073-1077, 1998					
	Tumbleson et al., "Advances in swine in biomedical research", <i>Plenum Press</i> , Bd. 2, 684, 1996					
	Trakshel et al., "Detection of Two Heme Oxygenase Isoforms in the Human Testis", <i>Biochem, Biophys. Res. Comm.</i> , 154(1): 285-291, 1988					S.
	Unterberg et al., "Reduced Acute Thrombus Formation Results in Decreased Neointimal Proliferation After Coronary Angioplasty", <i>J. Am. Coll. Cardiol</i> , 26: 1747-1754, 1995					
	Vingerhoeds et al	., "Immunoliposomes in Vivo",	Immunome	thods, 4: 259-272, 1994		
	Wickham et al., "Targeted Adenovirus Gene Transfer to Endothelial and Smooth Muscle Cells by Using Bispecific Antibodies", <i>Journ. of Virology</i> , 70(10): 6831-6838, 1996					
	Wong et al., "Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins", Science, 228: 810-815, 1985 (Abstract)					
	Yoshida et al., "Human heme oxygenase cDNA and induction of its mRNA by hemin", Eur. J. Biochem., 171:457-461, 1988					
- 1						
EXAMINER			DATE CO	NSIDERED		
	EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					f this